LabCompass

Mauricio Rojas

Medicine · The Ohio State University

Established · publishing since 1991

Publications

256

Citations

12,024

Est. group size

~3

Recurring co-author estimate

Active years

36

Publishing since 1991

Research summary
AI-generated

Mauricio Rojas conducts biomedical research focused on how the immune system contributes to autoimmune and inflammatory diseases such as lupus and rheumatoid arthritis, with particular attention to extracellular vesicles (tiny cell-released particles that carry molecular signals) and monocytes/macrophages (types of immune cells). A major applied direction of the work involves designing nanoparticle-based drug delivery systems that target specific immune cells to treat autoimmune conditions, alongside some work on lung disease, spatial transcriptomics, and reproductive biology in animals.

Extracellular vesicles in autoimmune diseaseNanoparticle drug delivery for immune-targeted therapyMonocyte and macrophage immune signalingSystemic lupus erythematosus and rheumatoid arthritisLung disease and mesenchymal stem cell biology

Publication output has gradually declined over the last decade, from around 14-17 papers per year in 2017-2021 to roughly 8-10 per year in recent years.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026

Publication cadence
Publications per year over the last 10 years — averaging 7.4/year recently
2017: 17 publications17172018: 11 publications182019: 14 publications192020: 11 publications202021: 17 publications17212022: 8 publications222023: 10 publications232024: 8 publications242025: 9 publications252026: 2 publications26
Recent publications
Publishes in
  • Figshare×8
  • bioRxiv (Cold Spring Harbor Laboratory)×6
  • Heliyon×4
  • Nanomedicine×4
  • Reproduction in Domestic Animals×3
Similar researchers
By research-topic overlap

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 19, 2026.

Claim or correct this profile